美国HFrEF住院患者SGLT2i处方现状:GWTG-HF注册研究
合并CKD者处方率更低,合并T2D者更高;仅9.4%患者出院时接受包含SGLT2i的四联治疗。医院间处方率差异显著,中位OR为2.51(95%CI 2.34-2.71)。
要点
- HFrEF住院患者出院SGLT2i处方率仅20.2%,合并CKD者更低。
- 仅9.4%患者出院时接受ACEI/ARB/ARNI+β受体阻滞剂+MRA+SGLT2i四联治疗。
- 医院间SGLT2i处方率差异大,74.6%医院处方率低于25%。
核心结论
- 符合条件的HFrEF住院患者出院时SGLT2i处方率低,合并CKD和T2D者亦然,且医院间差异显著。
研究设计与样本
- 排除eGFR低于20 mL/min/1.73 m2、1型糖尿病及既往SGLT2i不耐受者。
主要发现
- 9,988例(20.2%)出院时被处方SGLT2i。
关键数值与推荐
- 在461家年 eligible 出院≥10例的医院中,19家(4.1%)SGLT2i处方率≥50%,344家(74.6%)低于25%,其中29家(6.3%)为零处方。
- 未调整模型中医院间SGLT2i处方率中位OR为2.53(95%CI 2.36-2.74),调整患者和医院特征后中位OR为2.51(95%CI 2.34-2.71)。
临床怎么用
- HFrEF患者住院期间应评估并启动SGLT2i,尤其合并CKD或T2D者具有多重适应证。
- 应关注医院层面处方差异,识别并克服SGLT2i实施障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Nationwide adoption of SGLT2i for HFrEF in the US is unknown. OBJECTIVE: To characterize patterns of SGLT2i use among eligible US patients hospitalized for HFrEF. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study analyzed 49 399 patients hospitalized for HFrEF across 489 sites in the Get With The Guidelines-Heart Failure (GWTG-HF) registry between July 1, 2021, and June 30, 2022. Patients with an estimated glomerular filtration rate less than 20 mL/min/1.73 m2, type 1 diabetes, and previous intolerance to SGLT2i were excluded. MAIN OUTCOMES AND MEASURES: Patient-level and hospital-level prescription of SGLT2i at hospital discharge. RESULTS: Of 49 399 included patients, 16 548 (33.5%) were female, and the median (IQR) age was 67 (56-78) years. Overall, 9988 patients (20.2%) were prescribed an SGLT2i. SGLT2i prescription was less likely among patients with chronic kidney disease (CKD; 4550 of 24 437 [18.6%] vs 5438 of 24 962 [21.8%]; P < .001) but more likely among patients with type 2 diabetes (T2D; 5721 of 21 830 [26.2%] vs 4262 of 27 545 [15.5%]; P < .001) and those with both T2D and CKD (2905 of 12 236 [23.7%] vs 7078 vs 37 139 [19.1%]; P < .001). Patients prescribed SGLT2i therapy were more likely to be prescribed background triple therapy with an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, β-blocker, and mineralocorticoid receptor antagonist (4624 of 9988 [46.3%] vs 10 880 of 39 411 [27.6%]; P < .001), and 4624 of 49 399 total study patients (9.4%) were discharged with prescriptions for quadruple medical therapy including SGLT2i. Among 461 hospitals with 10 or more eligible discharges, 19 hospitals (4.1%) discharged 50% or more of patients with prescriptions for SGLT2i, whereas 344 hospitals (74.6%) discharged less than 25% of patients with prescriptions for SGLT2i (including 29 [6.3%] that discharged zero patients with SGLT2i prescriptions). There was high between-hospital variance in the rate of SGLT2i prescription in unadjusted models (median odds ratio, 2.53; 95% CI, 2.36-2.74) and after adjustment for patient and hospital characteristics (median odds ratio, 2.51; 95% CI, 2.34-2.71). CONCLUSIONS AND RELEVANCE: In this study, prescription of SGLT2i at hospital discharge among eligible patients with HFrEF was low, including among patients with comorbid CKD and T2D who have multiple indications for therapy, with substantial variation among US hospitals. Further efforts are needed to overcome implementation barriers and improve use of SGLT2i among patients with HFrEF.
引用
- Pierce JB, Vaduganathan M, Fonarow GC, et al. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2023. PMID: 37212192. doi:10.1001/jamacardio.2023.1266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。